

Arvin Ighani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3431754/publications.pdf>

Version: 2024-02-01

28
papers

425
citations

687363

13
h-index

752698

20
g-index

28
all docs

28
docs citations

28
times ranked

586
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and safety of switching to ixekizumab in secukinumab nonresponders with plaque psoriasis: A multicenter retrospective study of interleukin 17A antagonist therapies. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 155-157.	1.2	42
2	Drug survival of secukinumab in real-world plaque psoriasis patients: A 52-week, multicenter, retrospective study. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 1019-1020.	1.2	37
3	Biologic Treatment in Elderly Patients With Psoriasis: A Systematic Review. <i>Journal of Cutaneous Medicine and Surgery</i> , 2020, 24, 174-186.	1.2	29
4	Comparison of Management Guidelines for Moderate-to-Severe Plaque Psoriasis: A Review of Phototherapy, Systemic Therapies, and Biologic Agents. <i>Journal of Cutaneous Medicine and Surgery</i> , 2019, 23, 204-221.	1.2	28
5	Efficacy and safety of secukinumab in treating moderate to severe plaque psoriasis in two real-world Canadian dermatology clinics: a multicenter retrospective study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, e32-e34.	2.4	27
6	Short-term reasons for withdrawal and adverse events associated with apremilast therapy for psoriasis in real-world practice compared with in clinical trials: A multicenter retrospective study. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 801-803.	1.2	27
7	A comparison of apremilast monotherapy and combination therapy for plaque psoriasis in clinical practice: A Canadian multicenter retrospective study. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 623-626.	1.2	25
8	Evaluation of long-term efficacy, safety, and reasons for discontinuation of dupilumab for moderate to severe atopic dermatitis in clinical practice: A retrospective cohort study. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 1530-1532.	1.2	23
9	Efficacy and Safety of Apremilast Monotherapy for Moderate to Severe Psoriasis: Retrospective Study. <i>Journal of Cutaneous Medicine and Surgery</i> , 2018, 22, 290-296.	1.2	21
10	Biologic switching between interleukin 17A antagonists secukinumab and ixekizumab: a 12-week, multicenter, retrospective study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, e7-e8.	2.4	20
11	Ixekizumab (Interleukin 17A Antagonist): 12-week Efficacy and Safety Outcomes in Real-world Clinical Practice. <i>Journal of Cutaneous Medicine and Surgery</i> , 2019, 23, 174-177.	1.2	18
12	Pyoderma gangrenosum and its impact on quality of life: a multicentre, prospective study. <i>British Journal of Dermatology</i> , 2019, 180, 672-673.	1.5	15
13	Short- and Long-Term Management of an Acute Pustular Psoriasis Flare: A Case Report. <i>Journal of Cutaneous Medicine and Surgery</i> , 2017, 21, 452-456.	1.2	14
14	Secukinumab dose optimization in adult psoriasis patients: A retrospective, multicenter case series. <i>JAAD Case Reports</i> , 2018, 4, 310-313.	0.8	14
15	Systemic Monotherapy Treatments for Generalized Pustular Psoriasis: A Systematic Review. <i>Journal of Cutaneous Medicine and Surgery</i> , 2018, 22, 591-601.	1.2	13
16	Medical, Surgical, and Wound Care Management of Ulcerated Infantile Hemangiomas: A Systematic Review. <i>Journal of Cutaneous Medicine and Surgery</i> , 2018, 22, 495-504.	1.2	12
17	Satisfaction and Awareness of Systemic Psoriasis Treatments: A National Survey Comparing Biologic and Nonbiologic Users. <i>Journal of Cutaneous Medicine and Surgery</i> , 2019, 23, 148-156.	1.2	11
18	Maintenance of therapeutic response after 1 year of apremilast combination therapy compared with monotherapy for the treatment of plaque psoriasis: A multicenter, retrospective study. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 953-956.	1.2	10

#	ARTICLE	IF	CITATIONS
19	Off-Label High-Dose Secukinumab for the Treatment of Moderate-to-Severe Psoriasis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2019, 23, 391-393.	1.2	10
20	Tofacitinib for the treatment of psoriasis and psoriatic arthritis. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2020, 155, 400-410.	0.8	9
21	Comparative 12-week effectiveness and safety outcomes of biologic agents ustekinumab, secukinumab and ixekizumab for the treatment of plaque psoriasis: a real-world multicenter retrospective study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e416-e418.	2.4	6
22	An Evaluation of Psoriasis Patient Perceptions and Understanding of Biosimilars: A Canadian Survey Comparing Biologic and Nonbiologic Users. <i>Journal of Cutaneous Medicine and Surgery</i> , 2018, 22, 365-367.	1.2	4
23	Long-term 52-week trends in apremilast safety outcomes for treatment of psoriasis in clinical practice: a multicentre, retrospective case series. <i>British Journal of Dermatology</i> , 2019, 180, 211-212.	1.5	3
24	Short-Term Evaluation of the Real-World Efficacy and Safety of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis: A Canadian Multicenter Retrospective Cohort Study. <i>Journal of Cutaneous Medicine and Surgery</i> , 2020, 24, 468-473.	1.2	3
25	Herpes: A Not So Simple(x) History. <i>JAMA Dermatology</i> , 2017, 153, 910.	4.1	2
26	Off-label Uses of Topical Pimecrolimus. <i>Journal of Cutaneous Medicine and Surgery</i> , 2019, 23, 442-448.	1.2	2
27	Patient-Centred Care When Treating Plaque Psoriasis With Secukinumab: Reasons for Discontinuing Treatment Outside of Randomized Controlled Trials. <i>Journal of Cutaneous Medicine and Surgery</i> , 2018, 22, 647-649.	1.2	0
28	AB0939...Off-label secukinumab dose escalation in the treatment of moderate-to-severe psoriasis: a multicenter, retrospective study. , 2018, , .		0